Birchview Capital LP recently announced the acquisition of new stake in Aziyo Biologics Inc. (NASDAQ:AZYO). The institutional investor has increased its shareholding in the Healthcare company by 5.92% to 1.5 million shares with purchase of 84000.0 shares. This fresh investment now brings its stake to 12.72% valued currently at $6.38 million. In addition, Endurant Capital Management LP raised its holdings by 6749.0 to 1.14 million shares. And Geode Capital Management LLC has lifted its position by 3.91% or 402.0 shares – to 10677.0 shares.
With over 0.16 million Aziyo Biologics Inc. (AZYO) shares trading Tuesday and a closing price of $4.79 on the day, the dollar volume was approximately $0.76 million. The shares have shown a negative half year performance of -27.97% and its price on 01/24/23 gained nearly 11.03%. Currently, there are 13.66M common shares owned by the public and among those 11.67M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 3 analysts who have offered their price forecasts for AZYO have a consensus price objective of $12.00. The analysts have set the share’s price value over the next 12 months at a high of $13.00 and a low of $10.00. The average price target is 60.08% above its recent price level and an upside to the estimated low will see the stock gain 52.1% over that period. But an upside of 63.15% will see the stock hit the forecast high price target while median target price for the stock is $13.00.
Insiders at the company have transacted a total of 20 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 15 of these insider trades were purchases, accounting for 824,763 shares. Insider sales of the common stock occurred on 5 occasions, with total insider shares sold totaling 16,033 shares.
The top 3 mutual fund holders in Aziyo Biologics Inc. are Vanguard Total Stock Market Index, Bridgeway Ultra Small Company Mar, and Vanguard Extended Market Index Fu. Vanguard Total Stock Market Index owns 0.2 million shares of the company’s stock, all valued at over $0.83 million. The company bought an additional 0.13 million shares recently to bring their total holdings to about 1.66% of the shares outstanding. Vanguard Extended Market Index Fu now owns shares totaling to 0.10% of the shares outstanding.
Shares of Aziyo Biologics Inc. (NASDAQ: AZYO) opened at $4.43, up $0.12 from a prior closing price of $4.31. However, the script later moved the day high at 5.0100, up 11.03%. The company’s stock has a 5-day price change of 22.82% and -31.67% over the past three months. AZYO shares are trading 12.71% year to date (YTD), with the 12-month market performance down to -12.43% lower. It has a 12-month low price of $3.37 and touched a high of $9.01 over the same period. AZYO has an average intraday trading volume of 32.68K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 19.75%, -4.38%, and -22.71% respectively.
Institutional ownership of Aziyo Biologics Inc. (NASDAQ: AZYO) shares accounts for 28.70% of the company’s 13.66M shares outstanding. Mutual fund holders own 26.80%, while other institutional holders and individual stakeholders account for 55.29% and 2.13% respectively.
It has a market capitalization of $75.35M. The earnings-per-share (ttm) stands at -$2.83. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.25% over the week and 7.62% over the month.
Analysts forecast that Aziyo Biologics Inc. (AZYO) will achieve an EPS of -$0.66 for the current quarter, -$0.65 for the next quarter and -$2.34 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.69 while analysts give the company a high EPS estimate of -$0.61. Comparatively, EPS for the current quarter was -$0.81 a year ago. Earnings per share for the fiscal year are expected to increase by 4.00%, and 16.90% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 3 brokerage firm advisors rate Aziyo Biologics Inc. (AZYO) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 3 Wall Street analysts polled rate the stock as a buy, while 0 of the 3 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the AZYO, a number of firms have released research notes about the stock. Truist stated their Buy rating for the stock in a research note on November 02, 2020, with the firm’s price target at $20. Piper Sandler coverage for the Aziyo Biologics Inc. (AZYO) stock in a research note released on November 02, 2020 offered a Overweight rating with a price target of $20. Cowen was of a view on November 02, 2020 that the stock is Outperform, while Cantor Fitzgerald gave the stock Overweight rating on November 02, 2020, issuing a price target of $20.